Commons Sense

House of Commons · Written Ministerial Statement

UK Life Sciences

22 June 2022 · Department of Health and Social Care

Proposed by Sajid Javid Con Bromsgrove

NHSScience & Technology

Summarised by AI from the official record, so it can contain mistakes.

View on Parliament.uk

At a glance

Key points

  • The Government has agreed to Heads of Terms with Moderna for a strategic partnership over the next decade.
  • The partnership includes establishing a Global Research & Development Centre in the UK.
  • A binding contract will be negotiated and finalized by early Autumn, subject to approval of a Full Business Case.

Issue summary

The statement addresses the ongoing importance of strengthening the UK's life sciences sector to enhance resilience against future pandemics and threats.

Action requested

The Government has agreed Heads of Terms with Moderna for a strategic partnership over the next decade, which includes establishing a Global Research & Development Centre in the UK. A binding contract will be negotiated and finalized by early Autumn, subject to approval of a Full Business Case.

Key facts

  • Over £380 million invested in securing and scaling up vaccine manufacturing capabilities.
  • Government made available £9.6 billion for key COVID-19 programmes and related health spending.
  • Heads of Terms agreed with Moderna for a strategic partnership over the next decade, to be finalized by early Autumn.
  • A new state-of-the-art manufacturing facility will produce respiratory vaccines, offering UK priority access in future emergencies.
▸ Assessment & feedback
Summary accuracy